SCTC21C not checked

Sinocelltech

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
5 active
5 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“Pharmaceutical form: Solution for infusion; Route of administration: Subcutaneous”In the company’s words, NCT07297329 on ClinicalTrials.gov
Tested for
Multiple Myeloma (MM), Amyloidosis, Systemic Lupus Erythematosus (SLE), IgA Nephropathy, Relapsed or Refractory Hematologic Malignancies
Main trialPhase 3
“The purpose of this study is to evaluate if the addition of SCTC21C to bortezomib, lenalidomide and dexamethasone (VRd) in patients with newly diagnosed multiple myeloma not eligible for transplant will prolong progression-free survival (PFS) and/or improve overall minimal residual disease (MRD) negativity rate compared with VRd alone.”In the company’s words, NCT07297329 on ClinicalTrials.gov

Other drugs for Multiple Myeloma (MM)

All 133 drugs for Multiple Myeloma (MM)

Coming up4

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials5

TrialPhaseCompletesWhat it tests
Phase 3Recruiting Dec 2027 A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Phase 3Recruiting Dec 2027 A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis (NDSLCA)
Phase 1/2Not yet recruiting Apr 2027 A Clinica Study of SCTC21C in Participants With Systemic Lupus Erythematosus
Phase 1/2Not yet recruiting Sep 2027 A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune Diseases
Phase 1Recruiting 28 Aug 2025 A Clinical Study of SCTC21C in Participants With CD38+ Hematologic Malignancies
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow SCTC21C

Following is part of Solo: you see every change to SCTC21C the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in